Related Experiment Video

Updated: May 3, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.2K

Antivitamin K drugs in stroke prevention

Domenico Di Raimondo, Antonino Tuttolomondo, Carmelo Buttà

  • 1Dipartimento Biomedico di Medicina Interna e Specialistica, Università degli Studi di Palermo, Palermo, Italy. domenico.diraimondo@unipa.it.

Current Vascular Pharmacology
|February 4, 2014
PubMed

Insights

Cardioembolic stroke, often caused by atrial fibrillation, requires specific treatment. While Vitamin K antagonists are effective, new anticoagulants may offer better alternatives for stroke prevention.

Area of Science:

  • Neurology
  • Cardiology
  • Pharmacology

Background:

  • Approximately 20% of ischemic strokes are cardioembolic, with atrial fibrillation being the most frequent cause.
  • Treatment decisions for transient ischemic attack (TIA) and ischemic stroke hinge on identifying cardioembolic versus arterial origins.
  • Vitamin K antagonists (VKAs) are effective for preventing recurrent ischemic stroke but are underutilized due to limitations.

Purpose of the Study:

  • To review the efficacy and limitations of current anticoagulation and antiplatelet therapies for cardioembolic stroke.
  • To discuss the role of Vitamin K antagonists (VKAs) and antiplatelet agents in secondary stroke prevention.
  • To consider emerging anticoagulant therapies in light of clinical challenges associated with VKAs.

Main Methods:

  • Literature review of studies on stroke etiology, treatment guidelines, and anticoagulant/antiplatelet drug efficacy.
  • Analysis of current recommendations for secondary prevention in TIA and ischemic stroke.
  • Evaluation of clinical data on Vitamin K antagonists (VKAs) and newer oral anticoagulants.

Main Results:

  • Vitamin K antagonists (VKAs) at INR 2.0-3.0 remain guideline-recommended for cardioembolic stroke when tolerated.
  • Antiplatelet therapy is less effective than VKAs but serves as an alternative when anticoagulation is contraindicated or not feasible.
  • Newer anticoagulants (Factor Xa and thrombin inhibitors) show promise in addressing VKA-related clinical issues.

Conclusions:

  • Optimal secondary prevention for cardioembolic stroke requires careful consideration of patient factors and available therapies.
  • Vitamin K antagonists (VKAs) are effective but limited; newer anticoagulants warrant consideration for improved patient outcomes.
  • Future management strategies should incorporate data from trials on novel anticoagulants to overcome limitations of current treatments.

More Related Videos

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

14.4K
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

3.2K

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Hemorrhagic Stroke ll: Pathophysiology01:29

Hemorrhagic Stroke ll: Pathophysiology

A hemorrhagic stroke develops when a cerebral blood vessel ruptures, allowing blood to escape into the surrounding brain tissue, as in intracerebral hemorrhage (ICH), or into the subarachnoid space, as in subarachnoid hemorrhage (SAH). Because the skull is a rigid compartment, the sudden presence of extravascular blood rapidly increases intracranial pressure and compresses adjacent neural structures, leading to immediate tissue injury and impaired cerebral perfusion.Mass Effect and Primary...
30
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
415